NAVB lol, I think shorts are doing all they can to cover on the bid. They sit back to far and bulls get in front. It is a problem for them. The Alzheimer imaging agent in p3 is the elephant in the room now. Their revenues will grow as Lymphseek gains traction, so money won't be a problem,

it is the promise of the huge market that neuroimaging will bring that will drive this in the future.